结直肠癌术中应用雷替曲塞腹腔灌注化疗的安全性研究

目的 探讨结直肠癌术中应用雷替曲塞腹腔灌注化疗的安全性.方法 将60例行结直肠癌手术患者按照随机数字表法分为试验组(30例)和对照组(30例).试验组采用手术+术中雷替曲塞腹腔灌注化疗,对照组采用手术+术中生理盐水腹腔灌注治疗.评价两组患者血常规、肝肾功能的变化情况以及术后不良反应、并发症的发生率.结果 试验组手术前后白细胞分别为(6.36±2.63)×109/L、(8.20±2.08)×109/L,差异有统计学意义(t=3.06,P＜0.05);中性粒细胞比例分别为65.17％±10.36％ 、72.21％±10.53％,差异有统计学意义(t=3.22,P＜0.05);血小板分别为(261.03 ±84.74)×109/L、(228.47±58.69)×109/L,差异有统计学意义(t=2.07,P＜0 05).试验组术后白细胞、中性粒细胞比例、血小板与对照组相比,差异均无统计学意义(均P＞0.05).试验组1～2级恶心(60.00％∶23.33％;x2=8.30,P＜0.05)和呕吐(30.00％∶6.67％;x2=5.46,P＜0.05)的发生率明显高于对照组.其他不良反应的发生率两组比较差异均无统计学意义(均P ＞0.05).与对照组比较,试验组肠梗阻(6.67％∶3.33％,x2 =0.35,P＞0.05)、切口感染(10.00％∶6.67％,x2=0.22,P＞0.05)、腹腔出血(0∶0)、吻合口瘘(3.33％∶0,P＞0.05)发生率差异均无统计学意义.结论 结直肠癌术中使用雷替曲塞进行腹腔灌注化疗,不良反应可耐受,不增加术后并发症,治疗过程安全可行.

Safty research of intraoperative intraperitoneal chemotherapy with raltitrexed for advanced colorectal cancer

Objective To investigate the intraoperative intraperitoneal chemotherapy security with raltitrexed in advanced colorectal cancer surgical operation.Methods Sixty patients with colorectal cancer undergone surgery were randomly divided into trial group (n =30) and control group (n =30) according to the random number table method.The trial group was given surgical operation plus with intraperitoneal chemotherapy with raltitrexed.The control group was given surgical operation plus with intraperitoneal saline perfusion.Theroutine blood test,liver and kidney functions,toxic side effects and complications in two groups before and after surgery were investigated.Results The white blood cells in trial group before and after surgery was (6.36 ± 2.63) × 109/L vs.(8.20 ± 2.08) × 109/L,with statistically significant difference (t =3.06,P ＜0.05).The ratio of absolute neutrophil count in trial group before and after surgery was 65.17％ ± 10.36％ vs.72.21％ ± 10.53％ (t =3.22,P ＜ 0.05).The platelets in trial group before and after surgery was (261.03 ±84.74) × 109/L vs.(228.47 ± 58.69) × 109/L (t =2.07,P ＜ 0.05).The white blood cells,the ratio of absolute neutrophil count and the platelets after surgery had no statistically significant differeuces between the two groups (P ＞0.05).The trial group had higher 1,2 level vomiting (60.00％ vs.23.33％;x2 =8.30,P ＜ 0.05),and nausea (30.00％ vs.6.67％;x2 =5.46,P ＜ 0.05) incidence rates,but there was no statistically significant difference in other toxic side effects (P ＞ 0.05).The major complications post operation included intestinal obstruction,incision infection,abdominal cavity bleeding,and anastomotic fistula.There were equivalent complications in two groups (6.67％ vs.3.33％,x2 =0.35,P ＞0.05;10.00％ vs.6.67％,x2 =0.22,P＞0.05;0 vs.0;3.33％ vs.0,P＞0.05).Conclusion For patients with advanced colorectal cancer,intraoperative intraperitoneal chemotherapy with raltitrexed is safe and feasible,and the adverse reactions can be tolerated without increasing postoperative complications.